» Articles » PMID: 28928908

Epithelial Plasticity and Cancer Stem Cells: Major Mechanisms of Cancer Pathogenesis and Therapy Resistance

Overview
Date 2017 Sep 21
PMID 28928908
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-mesenchymal transition (EMT) has been linked with aggressive tumor biology and therapy resistance. It plays central role not only in the generation of cancer stem cells (CSCs) but also direct them across the multiple organ systems to promote tumor recurrence and metastasis. CSCs are reported to express stem cell genes as well as specific cell surface markers and allow aberrant differentiation of progenies. It facilitates cancer cells to leave primary tumor, acquire migratory characteristics, grow into new environment and develop radio-chemo-resistance. Based on the current information, present review discusses and summarizes the recent advancements on the molecular mechanisms that derive epithelial plasticity and its major role in generating a subset of tumor cells with stemness properties and pathophysiological spread of tumor. This paper further highlights the critical need to examine the regulation of EMT and CSC pathways in identifying the novel probable therapeutic targets. These improved therapeutic strategies based on the co-administration of inhibitors of EMT, CSCs as well as differentiated tumor cells may provide improved anti-neoplastic response with no tumor relapse.

Citing Articles

Preoperative Locoregional Therapy May Relate with Stemness and Distinct Transitions Between Epithelial and Mesenchymal States in Hepatocellular Carcinoma.

Espirito Santo J, Ladeirinha A, Alarcao A, Strelet E, Reis M, Santos R J Clin Exp Hepatol. 2023; 14(1):101268.

PMID: 38076372 PMC: 10709210. DOI: 10.1016/j.jceh.2023.08.004.


Regulating POLR3G by MicroRNA-26a-5p as a promising therapeutic target of lung cancer stemness and chemosensitivity.

Park C, Lee M, Lee S, Kang D, Park S, Lee D Noncoding RNA Res. 2023; 8(3):273-281.

PMID: 36949748 PMC: 10025963. DOI: 10.1016/j.ncrna.2023.03.001.


Cancer Stem Cells-The Insight into Non-Coding RNAs.

Bryl R, Piwocka O, Kawka E, Mozdziak P, Kempisty B, Knopik-Skrocka A Cells. 2022; 11(22).

PMID: 36429127 PMC: 9688207. DOI: 10.3390/cells11223699.


Polyphyllin VII as a Potential Drug for Targeting Stemness in Hepatocellular Cancer STAT3 Signaling.

Xu L, Chen Z, Wang Y, Li Y, Wang Z, Li F Curr Cancer Drug Targets. 2022; 23(4):325-331.

PMID: 36284387 DOI: 10.2174/1568009623666221024103834.


The Quasimesenchymal Pancreatic Ductal Epithelial Cell Line PANC-1-A Useful Model to Study Clonal Heterogeneity and EMT Subtype Shifting.

Ungefroren H, Thurling I, Farber B, Kowalke T, Fischer T, de Assis L Cancers (Basel). 2022; 14(9).

PMID: 35565186 PMC: 9101310. DOI: 10.3390/cancers14092057.


References
1.
Chung C, Aulino J, Muldowney N, Hatakeyama H, Baumann J, Burkey B . Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2009; 21(4):864-870. PMC: 2844946. DOI: 10.1093/annonc/mdp390. View

2.
Dykxhoorn D, Wu Y, Xie H, Yu F, Lal A, Petrocca F . miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 2009; 4(9):e7181. PMC: 2749331. DOI: 10.1371/journal.pone.0007181. View

3.
Naujokat C, Steinhart R . Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012; 2012:950658. PMC: 3516046. DOI: 10.1155/2012/950658. View

4.
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T . Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005; 5(9):744-9. DOI: 10.1038/nrc1694. View

5.
Onnis B, Rapisarda A, Melillo G . Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009; 13(9A):2780-6. PMC: 2832082. DOI: 10.1111/j.1582-4934.2009.00876.x. View